INTRODUCTION AND OBJECTIVES: Gold Nanoparticles (GNP) mediated laser ablation has been shown to be biocompatible and safe for the treatment of focal cancer. Herein, we report the first 11 cases in the world using GNP-directed focal laser ablation of prostate tumors using ultrasound (US) and MR/US fusion technology (NCT NCT02680535).
METHODS: All patients were diagnosed with Gleason 7 or less prostate cancer with biopsy proven MR visible lesions and no disease other than appreciated on the MRI. Patients underwent ultra-focal laser ablation of the tumors using GNP with MR/US fusion guidance. Following infusion of intravenous GNP on Day 0, trans-perineal laser catheters were placed into the prostate lesions for GNP excitation/tumor ablation under MR/US fusion guidance using an electromagnetictracked MR/US fusion device (UroNav, Invivo Gainesville FL). At 48 hours post-ablation, the patient is imaged, followed by re-imaging and MR/US fusion guided biopsy (FBx) at 3 months. All patient demographics, clinical variables, and complications were recorded.
RESULTS: To date, 11 patients (mean age: 69.6 yrs; range 58-79 yrs) have been enrolled in the trial. All patients were diagnosed with Gleason < 7. All patients had a solitary lesion with mean tumor volume 0.73 mL (range 0.6-1.87 cc). A single patient did not tolerate the cold IV infusion of the gold nano particles and was not able to undergo ablation the following day. 8 of 10 patients have completed the 3 month followup targeted biopsy as primary endpoint. Mean pre-treatment PSA was 7.84 ng/mL (range 5.5-12.3 ng/mL). Mean post-treatment PSA was 3.9 ng/mL (range 1.5-6.1 ng/mL; 50% reduction). Five out of eight patients (62.5%) did not have any cancer detected on follow up biopsy. Only 1 out of 8 patients had clinically significant cancer as per Delphi consensus criteria (Gleason score >6 or cancer > 3mm at Gleason score 6).
CONCLUSIONS: Recent trends toward less invasive image guided therapies have been seen as investigators pursue focal targeted therapies. This report is the first in-man demonstration of MR/US guided ultra-focal laser ablation of prostate tumors using GNP. Figure 1A) . Metabolic MR spectroscopy utilizing 13 C-labeled pyruvate now allows for clinical examination of tissue metabolism and characterization of metabolic pathways such as the CAC. The traditionally utilized substrate of [1-13 C]pyruvate however has limitations in that the labeled carbon does not enter the CAC and instead is lost as CO 2 ( Figure 1A, yellow carbon) . We propose the substrate [2-13 C]pyruvate, to better characterize changes in the CAC ( Figure 1A , red carbon) and potentially understand the metabolic changes in prostate cancer. Specifically, pyruvate can be processed in the CAC, reduced to lactate (Warburg effect) or alanine (transamination). By exposing prostate cancer to [2-
13 C]pyruvate and examining the relative ratios of Lactate, Glutamate, and Alanine, we can elucidate which metabolic pathways (CAC, Warburg, transamination) are utilized in prostate cancer pyruvate metabolism. The aim of this study was to characterize the ability of [2-13 C]pyruvate to quantify CAC, Warburg, and transamination metabolism of pyruvate in prostate cancer cells.
METHODS: Tumorigenic prostate cells LNCaP were exposed a medium containing [2-13 C]pyruvate for 4 hours. The metabolites were then extracted from the cell pellet and the incubation medium, and 13 C labeled compounds formed within the cell and those released into the medium were analyzed through NMR chemical shifts with focus on spikes associated with pyruvate, lactate, alanine, glutamate, and other compounds involved in the CAC. Dioxane was used as a standard for NMR characterization.
RESULTS: The hyperpolarized carbon from the [2-13 C]pyruvate can be traced in the downstream metabolites of the citric acid cycle, Warburg metabolism, and transamination by NMR analysis ( Figure 1B ). This allows for the ability to calculate the relative diversion of energy form pyruvate to the three pathways of transamination (74%), Warburg (16%), and CAC (10% . 199, No. 4S, Supplement, Monday, May 21, 2018 
